Focused On-demand Library for Hepatoma-derived growth factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P51858

UPID:

HDGF_HUMAN

Alternative names:

High mobility group protein 1-like 2

Alternative UPACC:

P51858; B3KU21; D3DVC9; Q5SZ07; Q5SZ08; Q5SZ09

Background:

Hepatoma-derived growth factor, also known as High mobility group protein 1-like 2, is a protein encoded by the gene with accession number P51858. It acts as a transcriptional repressor and exhibits mitogenic activity for fibroblasts, indicating its role in cell proliferation. Additionally, it is a heparin-binding protein, suggesting its involvement in various biological processes through interaction with heparin.

Therapeutic significance:

Understanding the role of Hepatoma-derived growth factor could open doors to potential therapeutic strategies. Its involvement in cell proliferation and interaction with heparin highlights its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.